Figure 3.

AMPs show broad inhibition across three clinical strains. AMPs shown in Table 2 originating from (a) indolicidin and (b) UyCT3 tested against strains pb3 (black), pb15 (light grey) and pb35 (dark grey). All AMPs tested at 40 μM. Serial dilutions were performed for pb35, pb15 and pb3 for indolicidin variants (c, e, g) and UyCT3 variants (d, f, h), respectively. All growth rates were normalized to ‘No AMP treatment’, and statistical comparisions were with the WT peptide. Error bars show the standard error of regression. *P value <0.05, **P value <0.01, ***P value <0.001.